2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery …

G Hindricks, T Potpara, N Dagres, E Arbelo… - European heart …, 2021 - academic.oup.com
MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)

S Umemura, H Arima, S Arima, K Asayama… - Hypertension …, 2019 - nature.com
The Japanese Society of Hypertension (JSH) revised the Guidelines for the Management of
Hypertension 2014 (JSH 2014), and published the JSH 2019. In the development of the JSH …

[PDF][PDF] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

P Kirchhof, S Benussi, D Kotecha… - Polish Heart …, 2016 - journals.viamedica.pl
Komisję ESC ds. Wytycznych Postępowania nadzoruje i koordynuje przygotowywanie
nowych wytycznych i stanowisk przez grupy robocze i inne grupy ekspertów. Komitet jest …

[HTML][HTML] Фибрилляция и трепетание предсердий. Клинические рекомендации 2020

МГ Аракелян, ЛА Бокерия, ЕЮ Васильева… - Российский …, 2021 - cyberleninka.ru
Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

Modifiable risk factors and atrial fibrillation

DH Lau, S Nattel, JM Kalman, P Sanders - Circulation, 2017 - Am Heart Assoc
There has been increasing focus on the rising burden of atrial fibrillation (AF) since the turn
of the millennium. The AF epidemic is projected not only to have an impact on morbidity and …

[HTML][HTML] 2020 Clinical guidelines for Atrial fibrillation and atrial flutter

MG Arakelyan, LA Bockeria… - Russian Journal of …, 2021 - russjcardiol.elpub.ru
clinical guidelines, atrial fibrillation, ischemic stroke, anticoagulant therapy, vitamin K
antagonists, direct oral anticoagulants, triple antiplatelet therapy, rhythm control, electrical …

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial

M Rienstra, AH Hobbelt, M Alings… - European Heart …, 2018 - academic.oup.com
Aims Atrial fibrillation (AF) is a progressive disease. Targeted therapy of underlying
conditions refers to interventions aiming to modify risk factors in order to prevent AF. We …

JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias

K Ono, Y Iwasaki, M Akao, T Ikeda, K Ishii… - Circulation …, 2022 - jstage.jst.go.jp
The Japanese Circulation Society (JCS) published the “Guidelines for Pharmacological
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …

Peripheral arterial disease

SM Conte, PR Vale - Heart, Lung and Circulation, 2018 - Elsevier
Peripheral arterial disease (PAD) affects 15% of the Australian population and is a powerful
and serious predictor of cardiovascular mortality yet continues to be under-recognised and …

A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on …

MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger… - The Lancet, 2016 - thelancet.com
Executive summary Elevated blood pressure is the strongest modifiable risk factor for
cardiovascular disease worldwide. Despite extensive knowledge about ways to prevent as …